MOACM
GEVA

Mutual of America Capital Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Mutual of America Capital Management’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-24,304
Closed -$2.37M – 1283
2015
Q1 		$2.37M Sell
24,304
-700
-3% -$74.1K 0.05% 629
2014
Q4 		$2.32M Buy
25,004
+397
+2% +$31.3K 0.05% 628
2014
Q3 		$1.69M Hold
24,607
– – 0.04% 761
2014
Q2 		$2.58M Sell
24,607
-1,489
-6% -$127K 0.06% 544
2014
Q1 		$2.17M Buy
26,096
+7,700
+42% +$712K 0.05% 638
2013
Q4 		$1.19M Buy
18,396
+278
+2% +$16.5K 0.03% 910
2013
Q3 		$1.15M Buy
18,118
+457
+3% +$22.5K 0.03% 872
2013
Q2 		$742K Buy
+17,661
New +$805K 0.02% 984

Mutual of America Capital Management's GEVA Position: Q2 2015 in Review

Mutual of America Capital Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 24,304 shares — an estimated $2.37M sold.

Mutual of America Capital Management first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $2.58M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Mutual of America Capital Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Mutual of America Capital Management sold 24,304 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $2.37M.
  • Mutual of America Capital Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Mutual of America Capital Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.58M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Mutual of America Capital Management's 13F filing for Q2 2015, filed 5 Aug 2015.